Clinical Trial

Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy

Study acronym: ANC-IIT-004
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy. The project will provide more robust evidence-based medical support for the use of long-acting granulocyte-stimulating agents in patients undergoing concurrent chemoradiotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Trial Details
NCT Number NCT07205536
Lead Sponsor Affiliated Hospital of Nantong University
Conditions Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy
Enrollment 30 participants
Start Date 2025-08-01
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-11